IL161408A0 - Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (tfpi) - Google Patents

Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (tfpi)

Info

Publication number
IL161408A0
IL161408A0 IL16140802A IL16140802A IL161408A0 IL 161408 A0 IL161408 A0 IL 161408A0 IL 16140802 A IL16140802 A IL 16140802A IL 16140802 A IL16140802 A IL 16140802A IL 161408 A0 IL161408 A0 IL 161408A0
Authority
IL
Israel
Prior art keywords
tfpi
sepsis
treatment
low dose
tissue factor
Prior art date
Application number
IL16140802A
Other languages
English (en)
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of IL161408A0 publication Critical patent/IL161408A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y10/00—Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Theoretical Computer Science (AREA)
  • Mathematical Physics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL16140802A 2001-10-15 2002-10-15 Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (tfpi) IL161408A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32880601P 2001-10-15 2001-10-15
PCT/US2002/032625 WO2003055442A2 (en) 2001-10-15 2002-10-15 Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (tfpi)

Publications (1)

Publication Number Publication Date
IL161408A0 true IL161408A0 (en) 2004-09-27

Family

ID=23282520

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16140702A IL161407A0 (en) 2001-10-15 2002-10-15 Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi)
IL16140802A IL161408A0 (en) 2001-10-15 2002-10-15 Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (tfpi)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL16140702A IL161407A0 (en) 2001-10-15 2002-10-15 Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi)

Country Status (17)

Country Link
US (2) US7674769B2 (de)
EP (2) EP1446138A4 (de)
JP (5) JP2005506345A (de)
KR (2) KR20050036867A (de)
CN (2) CN1604790A (de)
AU (2) AU2002365131B2 (de)
BR (2) BR0213293A (de)
CA (2) CA2463738A1 (de)
EA (2) EA200400549A1 (de)
HU (2) HUP0500472A2 (de)
IL (2) IL161407A0 (de)
IS (2) IS7224A (de)
MX (2) MXPA04003547A (de)
NO (2) NO20041996D0 (de)
PL (2) PL374506A1 (de)
WO (2) WO2003032904A2 (de)
ZA (2) ZA200403601B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002365131B2 (en) 2001-10-15 2007-03-01 Novartis Vaccines And Diagnostics, Inc. Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (TFPI)
ATE404176T1 (de) * 2003-01-08 2008-08-15 Novartis Vaccines & Diagnostic Stabilisierte lyophilisierte zubereitungen mit gewebefaktor-inhibitor (tfpi) oder varianten des gewebefaktor-inhibitors
ATE516306T1 (de) * 2003-08-13 2011-07-15 Novartis Vaccines & Diagnostic Verbessertes verfahren zur reinigung von tfpi und tfpi-analogen
CN101426520A (zh) * 2004-03-17 2009-05-06 诺华疫苗和诊断公司 通过给予组织因子途径抑制剂（tfpi）治疗社区获得性重症肺炎
CN101180074A (zh) * 2005-04-15 2008-05-14 诺华疫苗和诊断公司 通过施用组织因子通路抑制剂(tfpi)治疗严重社区获得性肺炎
US20090214506A1 (en) * 2005-05-06 2009-08-27 Novartis Ag Use of TFPI to Treat Severe Bacterial Infections
AU2006246721B2 (en) 2005-05-16 2012-12-13 Abbvie Biotechnology Ltd Use of TNF inhibitor for treatment of erosive polyarthritis
EP1906994B1 (de) * 2005-06-24 2014-04-23 Drugrecure ApS Atemwegs-administration von aktiviertem protein c bei entzündungskrankheiten, die den atemtrakt betreffen
AU2006272653A1 (en) * 2005-07-22 2007-02-01 Novartis Ag TFPI fragments as anti-microbial agents
US9624295B2 (en) 2006-04-10 2017-04-18 Abbvie Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
WO2009014633A1 (en) * 2007-07-20 2009-01-29 Trustees Of The University Of Pennsylvania Method of treating acute respiratory distress syndrome
WO2009129164A1 (en) * 2008-04-15 2009-10-22 Novartis Ag Pharmaceutical combinations of tfpi-fragments and an antibiotic
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
WO2012078968A2 (en) 2010-12-10 2012-06-14 Lifeline Scientific, Inc. Machine perfusion with complement inhibitors
JP2014520873A (ja) 2011-07-18 2014-08-25 ザ ユニバーシティ オブ メルボルン ｃ−Ｆｍｓアンタゴニストの使用
CA2854882C (en) 2011-11-15 2016-03-29 Asahi Kasei Pharma Corporation Medicament for therapeutic treatment and/or improvement of sepsis
MX2015014198A (es) 2013-04-12 2015-12-11 Morphosys Ag Anticuerpos cuyo objetivo es m-csf.
US11908581B2 (en) 2018-04-10 2024-02-20 Hill-Rom Services, Inc. Patient risk assessment based on data from multiple sources in a healthcare facility
US11504071B2 (en) 2018-04-10 2022-11-22 Hill-Rom Services, Inc. Patient risk assessment based on data from multiple sources in a healthcare facility
WO2023142096A1 (en) * 2022-01-30 2023-08-03 Westlake University Composition and method for preventing and/or treating clostridioides difficile infections caused by clade 2 strains

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4603106A (en) * 1982-02-22 1986-07-29 The Rockefeller University Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
JPS5896026A (ja) * 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
DE3219248A1 (de) 1982-05-21 1983-11-24 Solco Basel AG, Birsfelden Verfahren zur gewinnung zellatmungsfoerdernder wirkstoffe aus kaelberblut
DE3380726D1 (en) * 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4620948A (en) * 1982-12-22 1986-11-04 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4511502A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4711845A (en) * 1984-08-31 1987-12-08 Cetus Corporation Portable temperature-sensitive control cassette
US4569790A (en) * 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
US4530787A (en) * 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
EP0179861A1 (de) 1984-04-19 1986-05-07 Agracetus Verfahren und vektoren für die transformation von pflanzenzellen
US4572798A (en) * 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
US4847201A (en) * 1985-02-05 1989-07-11 Cetus Corporation DNA encoding for CSF-1 and accompanying recombinant systems
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4748234A (en) * 1985-06-26 1988-05-31 Cetus Corporation Process for recovering refractile bodies containing heterologous proteins from microbial hosts
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
CA1292686C (en) 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
CA1294215C (en) 1986-10-27 1992-01-14 Ze'ev Shaked Pharmaceutical compositions of recombinant beta-interferon and formulation processes
US5110730A (en) * 1987-03-31 1992-05-05 The Scripps Research Institute Human tissue factor related DNA segments
US5223427A (en) * 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
US4929700A (en) * 1987-04-16 1990-05-29 Cetus Corporation Production of purified, biologically active, bacterially produced recombinant human CSF-1
US5106833A (en) * 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
US4966852A (en) * 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
IL87171A (en) 1987-11-23 1995-08-31 Monsanto Co ANDC of human tissue factor inhibitor
US5219994A (en) * 1988-11-08 1993-06-15 W. Alton Jones Cell Science Center, Inc. Inhibitor of tissue factor activity
DK412389D0 (da) 1989-01-19 1989-01-19 Novo Nordisk As Fremgangsmaade til udvinding af oprenset epi protein fra en fermenteringsoploesning
DK408089D0 (da) 1989-08-18 1989-08-18 Novo Nordisk As Proteiner
DK148890D0 (da) 1990-06-19 1990-06-19 Novo Nordisk As Farmaceutisk praeparat
IE913004A1 (en) 1990-08-27 1992-03-11 Monsanto Co Anticoagulant combination of laci and sulfated¹polysaccharides
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
DK261490D0 (da) 1990-10-31 1990-10-31 Novo Nordisk As New pharmaceutical compound
US5212091A (en) * 1992-03-02 1993-05-18 Monsanto Company Method of producing tissue factor pathway inhibitor
US5276015A (en) 1992-03-18 1994-01-04 Washington University Method of inhibiting microvascular thrombosis
USRE36476E (en) 1992-03-18 1999-12-28 Washington University Method of inhibiting microvascular thrombosis
EP0643585B1 (de) * 1992-06-01 1999-12-15 Chiron Corporation Zusammensetzungen enthaltend Lipoprotein-Associated-Coagulation-Inhibitor (LACI) zur Herstellung eines Medikaments zur Behandlung von akuten oder chronischen Enzündungen
US6063764A (en) * 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
AU4408493A (en) 1992-06-11 1994-01-04 Washington University Prophylaxis and treatment of sepsis and sepsis-associated coagulation disorders
US5589359A (en) * 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
JP3571378B2 (ja) * 1994-09-30 2004-09-29 扶桑薬品工業株式会社 感染症診断用プローブ
JP3761914B2 (ja) * 1994-11-17 2006-03-29 財団法人化学及血清療法研究所 アンチトロンビンｉｉｉ及び組織因子凝固系インヒビター含有血栓症治療剤
US5914316A (en) 1994-12-16 1999-06-22 Washington University Method of inhibiting intimal hyperplasia
US5612363A (en) 1995-06-02 1997-03-18 Berlex Laboratories, Inc. N,N-di(aryl) cyclic urea derivatives as anti-coagulants
US5885781A (en) 1995-06-07 1999-03-23 Chiron Corporation Regulation of cytokine synthesis and release
PT1602667E (pt) 1995-06-07 2007-07-13 Searle Llc Formulação aquosa que compreende tfpi e agentes de solubilização
US6242414B1 (en) 1995-06-07 2001-06-05 Chiron Corporation Regulation of cytokine synthesis and release
US5888968A (en) 1995-06-07 1999-03-30 Chiron Corporation TFPI formulation
US5902582A (en) 1995-09-05 1999-05-11 Chiron Corporation Use of TFPI inhibitor for treatment of cancer
US5772629A (en) * 1995-10-23 1998-06-30 Localmed, Inc. Localized intravascular delivery of TFPI for inhibition of restenosis in recanalized blood vessels
US5736364A (en) 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
ATE254472T1 (de) 1996-03-25 2003-12-15 Chemo Sero Therapeut Res Inst Hemmstoff für die gefässneubildung, der den gewebefaktor-inhibitor (tfpi) enthält
US5977057A (en) * 1996-05-08 1999-11-02 The University Of Vermont And State Agricultural College Thrombosis prophylaxis for factor VLEIDEN carriers
CA2279345A1 (en) * 1997-01-31 1998-08-06 Human Genome Sciences, Inc. Tissue factor pathway inhibitor-3
US5981471A (en) 1997-02-06 1999-11-09 Entremed, Inc. Compositions and methods for inhibiting cellular proliferation
EA002149B1 (ru) 1997-04-28 2001-12-24 Эли Лилли Энд Компани Улучшенные способы приготовления активированного белка с
IL121191A0 (en) 1997-06-29 1997-11-20 Yeda Res & Dev Synthetic peptides and pharmaceutical compositions comprising them
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6824997B1 (en) * 1998-09-18 2004-11-30 Binax, Inc. Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
AU768075B2 (en) 1998-10-22 2003-12-04 Eli Lilly And Company Methods for treating sepsis
EP1131091B1 (de) 1998-11-20 2003-04-02 Eli Lilly And Company Behandlung von hämorrhagischem virusfieber mit protein c
AU4683299A (en) * 1999-06-11 2001-01-02 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Detection of streptococcus pneumoniae and immunization against streptococcus pneumoniae infection
WO2000077246A2 (en) 1999-06-14 2000-12-21 Novo Nordisk A/S A METHOD FOR IDENTIFYING A DRUG CANDIDATE HAVING AN INHIBITORY ACTION ON FVII-TF ACTIVITY, AND FVIIa/TF ACTIVITY INHIBITING COMPOUNDS
US6294648B1 (en) 1999-07-20 2001-09-25 Bayer Corporation Protein having proteinase inhibitor activity
US6180607B1 (en) 1999-08-05 2001-01-30 Christopher Davies Protein having proteinase inhibitor activity
BRPI0017437B8 (pt) 1999-10-04 2021-05-25 Chiron Corp composição farmacêutica estabilizada contendo polipeptídeo il-2, método para aumentar estabilidade de interleucina-2 em uma composição farmacêutica, e uma forma seca da composição
EP1251868A1 (de) 2000-01-06 2002-10-30 Eli Lilly & Company Kombinationstherapie zur behandlung entzündlicher und respiratorischer erkrankungen
EP1263943A1 (de) 2000-02-11 2002-12-11 Eli Lilly & Company Protein c derivate
KR20020081330A (ko) 2000-02-16 2002-10-26 노오쓰웨스턴 유니버시티 폴리펩토이드 폐 계면활성제
DE10022092A1 (de) 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
US7015194B2 (en) 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
US6756208B2 (en) 2001-02-28 2004-06-29 John H. Griffin Plasma glucosylceramide deficiency as risk factor for thrombosis and modulator of anticoagulant protein C
US6808927B2 (en) 2001-04-04 2004-10-26 American Diagnostica, Inc. Method of preparation of stabilized thrombin-activatable fibrinolysis inhibitor (TAFI) and methods of use thereof
DE10132307A1 (de) 2001-07-06 2003-01-30 Aventis Behring Gmbh Arzneizubereitung zur Inhalation von Antithrombin bei entzündlichen Lungenerkrankungen und ARDS
AU2002365131B2 (en) 2001-10-15 2007-03-01 Novartis Vaccines And Diagnostics, Inc. Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (TFPI)
US20020198138A1 (en) 2002-06-07 2002-12-26 Macias William Louis Combination therapy for the treatment of inflammatory and respiratory diseases

Also Published As

Publication number Publication date
PL372138A1 (en) 2005-07-11
HUP0500472A2 (hu) 2005-08-29
ZA200403601B (en) 2006-06-28
NO20041996D0 (no) 2004-05-14
AU2002365131B2 (en) 2007-03-01
EP1446138A2 (de) 2004-08-18
IL161407A0 (en) 2004-09-27
EA200400549A1 (ru) 2005-02-24
WO2003055442A3 (en) 2004-03-04
JP2005515214A (ja) 2005-05-26
BR0213292A (pt) 2006-05-23
JP2006008706A (ja) 2006-01-12
JP2006008704A (ja) 2006-01-12
JP2010006839A (ja) 2010-01-14
AU2002365131A1 (en) 2003-07-15
US7674769B2 (en) 2010-03-09
KR20040040489A (ko) 2004-05-12
CN1604790A (zh) 2005-04-06
JP2005506345A (ja) 2005-03-03
CA2463738A1 (en) 2003-07-10
IS7224A (is) 2004-04-15
MXPA04003547A (es) 2004-07-22
EP1446138A4 (de) 2007-03-14
NO20041997D0 (no) 2004-05-14
IS7223A (is) 2004-04-15
ZA200403690B (en) 2005-03-08
PL374506A1 (en) 2005-10-31
BR0213293A (pt) 2004-12-21
KR20050036867A (ko) 2005-04-20
CA2463655A1 (en) 2003-04-24
WO2003055442A2 (en) 2003-07-10
US20030139340A1 (en) 2003-07-24
US20030139339A1 (en) 2003-07-24
CN1604787A (zh) 2005-04-06
HUP0501111A2 (en) 2007-12-28
WO2003032904A3 (en) 2004-03-04
EP1446140A2 (de) 2004-08-18
AU2002340183B2 (en) 2008-11-13
EA200400548A1 (ru) 2005-06-30
EP1446140A4 (de) 2007-03-07
MXPA04003548A (es) 2004-07-22
WO2003032904A2 (en) 2003-04-24

Similar Documents

Publication Publication Date Title
IL161408A0 (en) Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (tfpi)
AU5977401A (en) Delivery devices for treatment of vascular disease
GB0126151D0 (en) Administration of medicaments by vaporisation
HK1073997A1 (en) Administration of agents for the treatment of inflammation
PL372925A1 (en) Prevention and treatment of restenosis by local administration of drug
NO20042993L (no) Formulering og doseringsform for kontrollert levering av terapeutiske midler
AU2003297621A8 (en) Medical devices for delivery of therapeutic agents
IL196301A0 (en) Medicament for the treatment of hapatitis c
PL370818A1 (en) Dosage form for treatment of diabetes mellitus
EP1416884A4 (de) Abgabe von mitteln mit therapeutischen eigenschaften
AU2002310325A1 (en) Use of ozone for the prevention of infection caused by medical devices
ZA200410229B (en) Administration of therapeutic viruses
HUP0401501A3 (en) Treating or preventing vascular inflammation using pharmaceutical compositions containing sterol absorption inhibitor(s)
AU2002248319A1 (en) Pharmaceutical composition for the prevention and treatment of scar tissue
GB0130677D0 (en) Medicaments and novel compounds
AU2002322263A1 (en) Eglin c based drugs for treatment of disease
HK1070561A1 (en) Use of specific dose of fandaparinux sodium for the treatment of acs
HUP0302535A3 (en) Peptide compounds, pharmaceutical compositions containing them and their use for treatment of no-mediated diseases
HUP0303029A3 (en) Use of pharmaceutical compositions containing cgmp-5pde inhibitors for treatment of wounds
IL178115A0 (en) Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor (tfpi)
IL158900A0 (en) Pharmaceutical compositions containing a tricyclic compound for the prevention or treatment of skin diseases
EP1451308A4 (de) Therapeutische verwendung von aziridinoverbindungen
DE60230609D1 (de) Verabreichung von nichtsteroidalen entzündungshemmenden wirkstoffen durch inhalation
GB0119115D0 (en) Formulation for treatment of gallstones
AU2002230156A1 (en) Medicinal composition for treatment of chronic cardiac failure